leisure time -WSS

leisure time

author：entertainment 2025-10-02 08:32:26 - browse：81444

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Color Health wants to make cancer screenings convenient

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

A clever new way to fix Medicaid and graduate medical education

MoonLake credibility takes another hit with mid

Pfizer is about to make a big push in cancer. Will investors listen?

leisure time

leisure time

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Diversify hospital leadership teams to protect BIPOC patient health

After affirmative action ruling, medical educators look to 'holistic review'

MoonLake credibility takes another hit with mid

Anesthesiologist group: stop taking Ozempic before surgery

STAT Executive Editor Rick Berke on STAT's 8th birthday

Heart attack and stroke risk calculators need revising

Ohio train derailment: Experts on toxic chemical risks

Wildfire smoke exposes gaps in outdoor worker protections

Change Healthcare cyberattack shows risk of industry consolidation

entertainment

Using force crossed my mind when examining a defiant young patient

STAT Madness 2024: Meet the contenders

Virtual repurposing can help discover new uses for existing drugs

Free speech concerns arise in wake of journal editor Eisen's firing

Are embryos people? Reproductive medicine's future depends on the answer

10 million people disenrolled from Medicaid over past six months

Wikipedia

focus

focus

hotspot